Steven C. Quay - 27 Mar 2026 Form 4 Insider Report for ATOSSA THERAPEUTICS, INC. (ATOS)

Reporting relationship: President & CEO, Director
Issuer ticker: ATOS
Reported as of: 27 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 31 Mar 2026, 16:57:01 UTC
Prior SEC filing: 30 Jan 2026
Source filing: View source filing
Reporting owner signature: Steven C. Quay

Key filing fact

Steven C. Quay filed Form 4 for ATOSSA THERAPEUTICS, INC. (ATOS) on 31 Mar 2026.

Key facts

This page summarizes Steven C. Quay's Form 4 filing for ATOSSA THERAPEUTICS, INC. (ATOS).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 31 Mar 2026, 16:57.

Change

Previous filing in this sequence was filed on 30 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001008227 Primary reporting owner

QUAY STEVEN C

Relationship: President & CEO, Director
Address: C/O ATOSSA THERAPEUTICS, INC.,, 1448 NW MARKET STREET, SUITE 500, SEATTLE
Signature: Steven C. Quay
Signature date: 31 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ATOS transaction

Common Stock

Award

Transaction value
Shares: +65,000
Change %: +282%
Price: $0.000000^*
Shares after: 88,038
Date: 27 Mar 2026
Ownership: Direct
Footnotes: F1, F2

ATOS holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,483
Date: 27 Mar 2026
Ownership: By Ensisheim Partners, LLC
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal annual installments on the first three anniversaries of March 26, 2026.

Footnote F2

On February 2, 2026, the Issuer effected a one-for-fifteen reverse stock split of its Common Stock (the "Reverse Stock Split"). The number of securities reported on this Form 4 has been adjusted to reflect the Reverse Stock Split.

Footnote F3

Ensisheim Partners, LLC ("Ensisheim") is wholly owned by the Reporting Person and Dr. Shu-Chih Chen. The Reporting Person and Dr. Chen share voting and investment power over the securities held by Ensisheim. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.